

REMARKS

In response to the Restriction Requirement mailed March 25, 2005, Applicant hereby elects Group VII (claims 28 and 29), drawn to a method for identifying a compound which binds to the polypeptide of claim 11, classified in class 435, subclass 7.1. Applicant has canceled claims 1-27 and 30-31, has amended claims 28 and 29 and has added new claims 32-43 drawn to the subject matter of Group VII.

Support for the amendment to claim 28 can be found in the claims as filed and in the specification at, for example, paragraph [00135]. Support for the amendment to claim 29 can be found in the specification at, for example, paragraphs [00210]-[00211]. Support for new claims 32 and 34 can be found in the specification at, for example, paragraph [00196]. Support for new claim 33 can be found in the specification at, for example, paragraph [00203]. Support for new claim 35 can be found in the specification at, for example, paragraph [00192]. Support for new claims 36, 42 and 43 can be found in the specification at, for example, paragraph [00121]. Support for new claims 38 and 39 can be found in the specification at, for example, paragraphs [00202]-[00203]. Support for new claim 41 can be found in the specification at, for example, paragraph [0052]. No new matter has been added. Claims 28-29 and 32-43 are pending upon entry of this amendment.

The Specification has been amended to delete blank spaces, to replace browser-executable code with information identifying the reference named in the code and to identify trademarks. No new matter has been added.

Applicant hereby reserves the right to traverse the above restriction with respect to non-elected Groups I – VI, VIII and IX claims (canceled claims 1-27 and 30-31) in this or subsequent applications.

This paper is being filed timely as a request for a two month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

21 June 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By Tracy M. Sioussat
Tracy M. Sioussat, Ph.D.
Registration No. 50,609
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-374-7679
Facsimile - 617-551-8820